N
182400
vs
C
CANF
Over the past 12 months, NKMax Co Ltd has underperformed CANF, delivering a return of 0% compared to the CANF's 89% drop.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd
KOSDAQ:182400
|
2 020
KRW
|
|||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
690
ILS
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
182400, CANF
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
N
|
NKMax Co Ltd
Revenue
|
|||||||||||
|
C
|
Can Fite Biopharma Ltd
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
182400, CANF
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
N
|
NKMax Co Ltd
KOSDAQ:182400
|
|||||||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
182400, CANF
Performance Gap
182400, CANF
Performance By Year
182400, CANF
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
